2026 Q1 -tulosraportti
Vain PDF
91 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.8. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 21.5. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 5.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenStrong reaction yesterday to Otsuka Pharmaceutical's good phase 3 data. They now have a first-mover advantage and easier administration with dosing every fourth week vs once a week. If Vera is not too far behind, they can still benefit from Otsuka paving the way.
8.7.Investing.com – Cantor Fitzgerald has reiterated its "Overweight" rating and $100.00 price target for Vera Therapeutics (NASDAQ:VERA) stock following the company's announcement of a major drug approval. Vera Therapeutics announced that its drug Trutakna (atacicept) has received accelerated approval for the treatment of IgA nephropathy. The approval is based on the drug's proven ability to reduce proteinuria. The company stated that it expects to launch the drug in the coming weeks. The announced price for Trutakna is $425,000 per year. According to Cantor Fitzgerald, this represents a market opportunity of over $20 billion in the United States alone, based on conservative assumptions. The stock has risen 87% in the past year and is currently trading at $42.96, giving it a market capitalization of $3.08 billion. The distribution structure is already fully in place, positioning the company well for a successful market launch. Cantor Fitzgerald expects a robust start for Trutakna, similar to that of Voyxact, which received 880 patient therapy registrations in its first full quarter after launch. Vera Therapeutics has a market capitalization of approximately $3 billion and reported cash reserves of $597 million as of the first quarter of 2026. Cantor Fitzgerald continues to believe the stock is undervalued, given the highly competitive landscape in the IgA nephropathy field and a multi-billion dollar market with room for multiple disease-modifying B-cell modulators. An analysis by InvestingPro supports this assessment and suggests that the stock is currently undervalued compared to its fair value. Further recent news also underscores the positive trend: Vera Therapeutics received accelerated approval from the U.S. Food and Drug Administration (FDA) for Trutakna for the treatment of primary IgA nephropathy. The approval is based on interim results from the ongoing ORIGIN-3 study, which demonstrated a significant reduction in proteinuria in patients treated with Trutakna. Following the approval, Vera Therapeutics announced a list price of $425,000 per patient per year for the treatment. In response, H.C. Wainwright raised its price target for Vera Therapeutics to $125 and maintained its "Buy" rating. Similarly, Guggenheim raised its price target to $76, also with a "Buy" recommendation. Furthermore, Jefferies reaffirmed its "Buy" rating with a price target of $60, noting the company's alignment with the FDA regarding an eGFR analysis plan for full regulatory approval. The eGFR data is expected in the third quarter of 2026. These developments highlight Vera Therapeutics' significant progress in the regulatory and commercialization process.9.7.I appreciate the warning, Charlie! I know the macro AI-bubble narrative is getting loud right now, but there is a method to my madness. **I’m not betting on generic, hyped-up AI software apps. I'm intentionally targeting the critical infrastructure and structural bottlenecks. ** Look at SK Hynix—Nvidia literally cannot build its Blackwell architecture without their HBM3E memory. And Rubrik isn't a luxury; with the EU’s strict NIS2 and DORA compliance deadlines hitting companies hard, cybersecurity infrastructure is non-discretionary spending. Even if Big Tech slows down general AI spending, the hardware foundation and security layers are locked in. It’s definitely a high-conviction, high-volatility ride, but I like being where the secular wind is blowing. Let's see if Claude sides with my infrastructure thesis or your macro caution when the dust settles! 🚀🐻
·21.6.Some thoughts on the possibilities for a run-up leading up to July 7th, when the FDA is to decide whether Vera gets accelerated approval for the atacicept drug?
·15.9.2025Any Vera holders? Very little activity here, get in the mood🎉📈8.7.Investing.com – Cantor Fitzgerald has reiterated its "Overweight" rating and $100.00 price target for Vera Therapeutics (NASDAQ:VERA) stock following the company's announcement of a major drug approval. Vera Therapeutics announced that its drug Trutakna (atacicept) has received accelerated approval for the treatment of IgA nephropathy. The approval is based on the drug's proven ability to reduce proteinuria. The company stated that it expects to launch the drug in the coming weeks. The announced price for Trutakna is $425,000 per year. According to Cantor Fitzgerald, this represents a market opportunity of over $20 billion in the United States alone, based on conservative assumptions. The stock has risen 87% in the past year and is currently trading at $42.96, giving it a market capitalization of $3.08 billion. The distribution structure is already fully in place, positioning the company well for a successful market launch. Cantor Fitzgerald expects a robust start for Trutakna, similar to that of Voyxact, which received 880 patient therapy registrations in its first full quarter after launch. Vera Therapeutics has a market capitalization of approximately $3 billion and reported cash reserves of $597 million as of the first quarter of 2026. Cantor Fitzgerald continues to believe the stock is undervalued, given the highly competitive landscape in the IgA nephropathy field and a multi-billion dollar market with room for multiple disease-modifying B-cell modulators. An analysis by InvestingPro supports this assessment and suggests that the stock is currently undervalued compared to its fair value. Further recent news also underscores the positive trend: Vera Therapeutics received accelerated approval from the U.S. Food and Drug Administration (FDA) for Trutakna for the treatment of primary IgA nephropathy. The approval is based on interim results from the ongoing ORIGIN-3 study, which demonstrated a significant reduction in proteinuria in patients treated with Trutakna. Following the approval, Vera Therapeutics announced a list price of $425,000 per patient per year for the treatment. In response, H.C. Wainwright raised its price target for Vera Therapeutics to $125 and maintained its "Buy" rating. Similarly, Guggenheim raised its price target to $76, also with a "Buy" recommendation. Furthermore, Jefferies reaffirmed its "Buy" rating with a price target of $60, noting the company's alignment with the FDA regarding an eGFR analysis plan for full regulatory approval. The eGFR data is expected in the third quarter of 2026. These developments highlight Vera Therapeutics' significant progress in the regulatory and commercialization process.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
91 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenStrong reaction yesterday to Otsuka Pharmaceutical's good phase 3 data. They now have a first-mover advantage and easier administration with dosing every fourth week vs once a week. If Vera is not too far behind, they can still benefit from Otsuka paving the way.
- 8.7.Investing.com – Cantor Fitzgerald has reiterated its "Overweight" rating and $100.00 price target for Vera Therapeutics (NASDAQ:VERA) stock following the company's announcement of a major drug approval. Vera Therapeutics announced that its drug Trutakna (atacicept) has received accelerated approval for the treatment of IgA nephropathy. The approval is based on the drug's proven ability to reduce proteinuria. The company stated that it expects to launch the drug in the coming weeks. The announced price for Trutakna is $425,000 per year. According to Cantor Fitzgerald, this represents a market opportunity of over $20 billion in the United States alone, based on conservative assumptions. The stock has risen 87% in the past year and is currently trading at $42.96, giving it a market capitalization of $3.08 billion. The distribution structure is already fully in place, positioning the company well for a successful market launch. Cantor Fitzgerald expects a robust start for Trutakna, similar to that of Voyxact, which received 880 patient therapy registrations in its first full quarter after launch. Vera Therapeutics has a market capitalization of approximately $3 billion and reported cash reserves of $597 million as of the first quarter of 2026. Cantor Fitzgerald continues to believe the stock is undervalued, given the highly competitive landscape in the IgA nephropathy field and a multi-billion dollar market with room for multiple disease-modifying B-cell modulators. An analysis by InvestingPro supports this assessment and suggests that the stock is currently undervalued compared to its fair value. Further recent news also underscores the positive trend: Vera Therapeutics received accelerated approval from the U.S. Food and Drug Administration (FDA) for Trutakna for the treatment of primary IgA nephropathy. The approval is based on interim results from the ongoing ORIGIN-3 study, which demonstrated a significant reduction in proteinuria in patients treated with Trutakna. Following the approval, Vera Therapeutics announced a list price of $425,000 per patient per year for the treatment. In response, H.C. Wainwright raised its price target for Vera Therapeutics to $125 and maintained its "Buy" rating. Similarly, Guggenheim raised its price target to $76, also with a "Buy" recommendation. Furthermore, Jefferies reaffirmed its "Buy" rating with a price target of $60, noting the company's alignment with the FDA regarding an eGFR analysis plan for full regulatory approval. The eGFR data is expected in the third quarter of 2026. These developments highlight Vera Therapeutics' significant progress in the regulatory and commercialization process.9.7.I appreciate the warning, Charlie! I know the macro AI-bubble narrative is getting loud right now, but there is a method to my madness. **I’m not betting on generic, hyped-up AI software apps. I'm intentionally targeting the critical infrastructure and structural bottlenecks. ** Look at SK Hynix—Nvidia literally cannot build its Blackwell architecture without their HBM3E memory. And Rubrik isn't a luxury; with the EU’s strict NIS2 and DORA compliance deadlines hitting companies hard, cybersecurity infrastructure is non-discretionary spending. Even if Big Tech slows down general AI spending, the hardware foundation and security layers are locked in. It’s definitely a high-conviction, high-volatility ride, but I like being where the secular wind is blowing. Let's see if Claude sides with my infrastructure thesis or your macro caution when the dust settles! 🚀🐻
- ·21.6.Some thoughts on the possibilities for a run-up leading up to July 7th, when the FDA is to decide whether Vera gets accelerated approval for the atacicept drug?
- ·15.9.2025Any Vera holders? Very little activity here, get in the mood🎉📈8.7.Investing.com – Cantor Fitzgerald has reiterated its "Overweight" rating and $100.00 price target for Vera Therapeutics (NASDAQ:VERA) stock following the company's announcement of a major drug approval. Vera Therapeutics announced that its drug Trutakna (atacicept) has received accelerated approval for the treatment of IgA nephropathy. The approval is based on the drug's proven ability to reduce proteinuria. The company stated that it expects to launch the drug in the coming weeks. The announced price for Trutakna is $425,000 per year. According to Cantor Fitzgerald, this represents a market opportunity of over $20 billion in the United States alone, based on conservative assumptions. The stock has risen 87% in the past year and is currently trading at $42.96, giving it a market capitalization of $3.08 billion. The distribution structure is already fully in place, positioning the company well for a successful market launch. Cantor Fitzgerald expects a robust start for Trutakna, similar to that of Voyxact, which received 880 patient therapy registrations in its first full quarter after launch. Vera Therapeutics has a market capitalization of approximately $3 billion and reported cash reserves of $597 million as of the first quarter of 2026. Cantor Fitzgerald continues to believe the stock is undervalued, given the highly competitive landscape in the IgA nephropathy field and a multi-billion dollar market with room for multiple disease-modifying B-cell modulators. An analysis by InvestingPro supports this assessment and suggests that the stock is currently undervalued compared to its fair value. Further recent news also underscores the positive trend: Vera Therapeutics received accelerated approval from the U.S. Food and Drug Administration (FDA) for Trutakna for the treatment of primary IgA nephropathy. The approval is based on interim results from the ongoing ORIGIN-3 study, which demonstrated a significant reduction in proteinuria in patients treated with Trutakna. Following the approval, Vera Therapeutics announced a list price of $425,000 per patient per year for the treatment. In response, H.C. Wainwright raised its price target for Vera Therapeutics to $125 and maintained its "Buy" rating. Similarly, Guggenheim raised its price target to $76, also with a "Buy" recommendation. Furthermore, Jefferies reaffirmed its "Buy" rating with a price target of $60, noting the company's alignment with the FDA regarding an eGFR analysis plan for full regulatory approval. The eGFR data is expected in the third quarter of 2026. These developments highlight Vera Therapeutics' significant progress in the regulatory and commercialization process.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.8. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 21.5. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 5.8.2025 |
2026 Q1 -tulosraportti
Vain PDF
91 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.8. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 21.5. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 5.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenStrong reaction yesterday to Otsuka Pharmaceutical's good phase 3 data. They now have a first-mover advantage and easier administration with dosing every fourth week vs once a week. If Vera is not too far behind, they can still benefit from Otsuka paving the way.
- 8.7.Investing.com – Cantor Fitzgerald has reiterated its "Overweight" rating and $100.00 price target for Vera Therapeutics (NASDAQ:VERA) stock following the company's announcement of a major drug approval. Vera Therapeutics announced that its drug Trutakna (atacicept) has received accelerated approval for the treatment of IgA nephropathy. The approval is based on the drug's proven ability to reduce proteinuria. The company stated that it expects to launch the drug in the coming weeks. The announced price for Trutakna is $425,000 per year. According to Cantor Fitzgerald, this represents a market opportunity of over $20 billion in the United States alone, based on conservative assumptions. The stock has risen 87% in the past year and is currently trading at $42.96, giving it a market capitalization of $3.08 billion. The distribution structure is already fully in place, positioning the company well for a successful market launch. Cantor Fitzgerald expects a robust start for Trutakna, similar to that of Voyxact, which received 880 patient therapy registrations in its first full quarter after launch. Vera Therapeutics has a market capitalization of approximately $3 billion and reported cash reserves of $597 million as of the first quarter of 2026. Cantor Fitzgerald continues to believe the stock is undervalued, given the highly competitive landscape in the IgA nephropathy field and a multi-billion dollar market with room for multiple disease-modifying B-cell modulators. An analysis by InvestingPro supports this assessment and suggests that the stock is currently undervalued compared to its fair value. Further recent news also underscores the positive trend: Vera Therapeutics received accelerated approval from the U.S. Food and Drug Administration (FDA) for Trutakna for the treatment of primary IgA nephropathy. The approval is based on interim results from the ongoing ORIGIN-3 study, which demonstrated a significant reduction in proteinuria in patients treated with Trutakna. Following the approval, Vera Therapeutics announced a list price of $425,000 per patient per year for the treatment. In response, H.C. Wainwright raised its price target for Vera Therapeutics to $125 and maintained its "Buy" rating. Similarly, Guggenheim raised its price target to $76, also with a "Buy" recommendation. Furthermore, Jefferies reaffirmed its "Buy" rating with a price target of $60, noting the company's alignment with the FDA regarding an eGFR analysis plan for full regulatory approval. The eGFR data is expected in the third quarter of 2026. These developments highlight Vera Therapeutics' significant progress in the regulatory and commercialization process.9.7.I appreciate the warning, Charlie! I know the macro AI-bubble narrative is getting loud right now, but there is a method to my madness. **I’m not betting on generic, hyped-up AI software apps. I'm intentionally targeting the critical infrastructure and structural bottlenecks. ** Look at SK Hynix—Nvidia literally cannot build its Blackwell architecture without their HBM3E memory. And Rubrik isn't a luxury; with the EU’s strict NIS2 and DORA compliance deadlines hitting companies hard, cybersecurity infrastructure is non-discretionary spending. Even if Big Tech slows down general AI spending, the hardware foundation and security layers are locked in. It’s definitely a high-conviction, high-volatility ride, but I like being where the secular wind is blowing. Let's see if Claude sides with my infrastructure thesis or your macro caution when the dust settles! 🚀🐻
- ·21.6.Some thoughts on the possibilities for a run-up leading up to July 7th, when the FDA is to decide whether Vera gets accelerated approval for the atacicept drug?
- ·15.9.2025Any Vera holders? Very little activity here, get in the mood🎉📈8.7.Investing.com – Cantor Fitzgerald has reiterated its "Overweight" rating and $100.00 price target for Vera Therapeutics (NASDAQ:VERA) stock following the company's announcement of a major drug approval. Vera Therapeutics announced that its drug Trutakna (atacicept) has received accelerated approval for the treatment of IgA nephropathy. The approval is based on the drug's proven ability to reduce proteinuria. The company stated that it expects to launch the drug in the coming weeks. The announced price for Trutakna is $425,000 per year. According to Cantor Fitzgerald, this represents a market opportunity of over $20 billion in the United States alone, based on conservative assumptions. The stock has risen 87% in the past year and is currently trading at $42.96, giving it a market capitalization of $3.08 billion. The distribution structure is already fully in place, positioning the company well for a successful market launch. Cantor Fitzgerald expects a robust start for Trutakna, similar to that of Voyxact, which received 880 patient therapy registrations in its first full quarter after launch. Vera Therapeutics has a market capitalization of approximately $3 billion and reported cash reserves of $597 million as of the first quarter of 2026. Cantor Fitzgerald continues to believe the stock is undervalued, given the highly competitive landscape in the IgA nephropathy field and a multi-billion dollar market with room for multiple disease-modifying B-cell modulators. An analysis by InvestingPro supports this assessment and suggests that the stock is currently undervalued compared to its fair value. Further recent news also underscores the positive trend: Vera Therapeutics received accelerated approval from the U.S. Food and Drug Administration (FDA) for Trutakna for the treatment of primary IgA nephropathy. The approval is based on interim results from the ongoing ORIGIN-3 study, which demonstrated a significant reduction in proteinuria in patients treated with Trutakna. Following the approval, Vera Therapeutics announced a list price of $425,000 per patient per year for the treatment. In response, H.C. Wainwright raised its price target for Vera Therapeutics to $125 and maintained its "Buy" rating. Similarly, Guggenheim raised its price target to $76, also with a "Buy" recommendation. Furthermore, Jefferies reaffirmed its "Buy" rating with a price target of $60, noting the company's alignment with the FDA regarding an eGFR analysis plan for full regulatory approval. The eGFR data is expected in the third quarter of 2026. These developments highlight Vera Therapeutics' significant progress in the regulatory and commercialization process.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt